News & Analysis as of

Sandoz › Regulatory Requirements › Samsung Bioepis

Goodwin

Denosumab Updates: Wyost and Jubbonti Launch as First Denosumab Biosimilars in the U.S.

Goodwin on

On June 2, 2025, Sandoz announced that WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are now available to patients in the United States. ...more

1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide